leisure time -WSS

leisure time

author：leisure time 2025-09-29 00:38:41 - browse：1413

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Grad students accuse University of California of wage theft

leisure time

WSS

Physicians and social media: If you see something, say something?

Senate bill would ban some hospital facility fees

Midwives could help bridge maternal health disparities in the U.S.

What happened to the House vote on health price transparency?

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Positive childhood experiences can help future health

focus

leisure time

entertainment

Hollywood unions extend contract negotiations for actors

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Trump demands the U.S. pay no more for drugs than other countries … again

Stop the failed accountable care organization experiment

Tori Bowie and the unacceptable rates of Black maternal death

Patients, doctors press FTC to beef up hospital merger scrutiny

The high cost of giving birth even with insurance

The struggle to figure out which patients 'deserve' Wegovy

Malaria cases in Florida and Texas: Here’s what you need to know

Senate bill would ban some hospital facility fees

entertainment

Patients, doctors press FTC to beef up hospital merger scrutiny

Free Covid tests will again be offered to all U.S. households

Eli Lilly CEO gives to Mike Pence presidential super PAC

PBMs drew scrutiny in House hearing — and so did pharma

Asbestos, a deadly carcinogen, banned by EPA

Nurses recount patients attacks

leisure time

hotspot

hotspot

hotspot